医院模板

Gastrointestinal (GI) tract infection and dysbiosis of gut microbiota are associated with some of the most common and serious medical conditions. TNP-2092 PO is a locally acting formulation specifically designed to target pathogens living in GI tract and symptoms associated dysbiosis of gut microbiota. Rifaximin, an RNA polymerase inhibitor, is one of the leading drugs on the market for the treatment of traveler’s diarrhea, hepatic encephalopathy and irritable bowel symptom-diarrhea (IBS-D). As a multi-targeting drug conjugate, TNP-2092 has the advantage of high potency and low propensity for development of resistance as compared to rifaximin. TNP-2092 is currently under clinical development for the treatment of cirrhosis hepatic encephalopathy, IBS-D and other conditions associated dysbiosis.